Analysts Set Momenta Pharmaceuticals, Inc. (MNTA) PT at $14.43

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) have been assigned a consensus rating of “Hold” from the eleven analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $14.43.

A number of equities analysts recently issued reports on the company. BidaskClub cut Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 18th. Stifel Nicolaus upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $18.00 to $21.00 in a report on Thursday, February 22nd. ValuEngine upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 23rd. Finally, TheStreet cut Momenta Pharmaceuticals from a “c-” rating to a “d” rating in a report on Tuesday, May 8th.

In related news, SVP Young Kwon sold 15,089 shares of the stock in a transaction on Thursday, April 19th. The stock was sold at an average price of $20.90, for a total value of $315,360.10. Following the completion of the sale, the senior vice president now directly owns 147,411 shares of the company’s stock, valued at approximately $3,080,889.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Craig A. Wheeler sold 1,772 shares of the stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $21.86, for a total value of $38,735.92. Following the completion of the sale, the chief executive officer now directly owns 198,987 shares of the company’s stock, valued at $4,349,855.82. The disclosure for this sale can be found here. Insiders sold a total of 174,558 shares of company stock valued at $3,512,669 over the last three months. 4.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MNTA. Tocqueville Asset Management L.P. increased its position in shares of Momenta Pharmaceuticals by 243.6% during the 4th quarter. Tocqueville Asset Management L.P. now owns 963,784 shares of the biotechnology company’s stock valued at $13,445,000 after purchasing an additional 683,296 shares during the last quarter. VHCP Management II LLC purchased a new stake in shares of Momenta Pharmaceuticals during the 1st quarter valued at $7,714,000. Rock Springs Capital Management LP purchased a new stake in shares of Momenta Pharmaceuticals during the 1st quarter valued at $6,262,000. BlackRock Inc. increased its position in shares of Momenta Pharmaceuticals by 2.7% during the 1st quarter. BlackRock Inc. now owns 10,755,588 shares of the biotechnology company’s stock valued at $195,213,000 after purchasing an additional 282,272 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Momenta Pharmaceuticals by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,583,000 shares of the biotechnology company’s stock valued at $22,083,000 after purchasing an additional 134,500 shares during the last quarter. 96.43% of the stock is owned by institutional investors and hedge funds.

Shares of Momenta Pharmaceuticals opened at $21.70 on Friday, according to Marketbeat Ratings. Momenta Pharmaceuticals has a 12-month low of $20.90 and a 12-month high of $21.90. The firm has a market capitalization of $1.63 billion, a P/E ratio of -18.08 and a beta of 1.63.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.19). Momenta Pharmaceuticals had a negative return on equity of 28.56% and a negative net margin of 88.77%. The firm had revenue of $4.85 million during the quarter, compared to the consensus estimate of $15.63 million. During the same quarter in the prior year, the business earned ($0.46) earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was down 81.8% on a year-over-year basis. analysts predict that Momenta Pharmaceuticals will post -1.34 earnings per share for the current year.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply